Abstract
With the rapid spread of COVID-19, there is an urgent need for a framework to accurately predict COVID-19 transmission. Recent epidemiological studies have found that a prominent feature of COVID-19 is its ability to be transmitted before symptoms occur, which is generally not the case for seasonal influenza and SARS. Several COVID-19 predictive epidemiological models have been proposed; however, they share a common drawback—they are unable to capture the unique asymptomatic nature of COVID-19 transmission. Here, we propose vector autoregression (VAR) as an epidemiological county-level prediction model that captures this unique aspect of COVID-19 transmission by introducing newly infected cases in other counties as lagged explanatory variables. Using the number of new COVID-19 cases in seven New York State counties, we predicted new COVID-19 cases in the counties over the next 4 weeks. We then compared our prediction results with those of 11 other state-of-the-art prediction models proposed by leading research institutes and academic groups. The results showed that VAR prediction is superior to other epidemiological prediction models in terms of the root mean square error of prediction. Thus, we strongly recommend the simple VAR model as a framework to accurately predict COVID-19 transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
https://usafacts.org/visualizations/coronavirus-covid-19-spread-map